diphenhydramine has been researched along with carboplatin in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fanning, J; Hilgers, RD | 1 |
| Broome, CB; Friedman, HS; Schiff, RI | 1 |
| Jobe, DR; Kuhn, J; Rizzo, J; Schreeder, MT; Walton, GD | 1 |
| Belt, R; Coon, J; Cord, M; Dix, S; Geller, R; Howard, S | 1 |
| Friedlander, M; Jones, R; Ryan, M | 1 |
| Fujii, T; Komatsu, M; Kumagai, M; Kusuda, T; Naitou, H; Shinkou, S; Takehara, K | 1 |
| Asmar, L; Dakhil, S; Friedland, DM; Gregurich, MA; Hollen, C | 1 |
| Bafaloukos, D; Bakogiannis, C; Bamias, A; Boukovinas, I; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Kalofonos, HP; Kosmidis, PA; Makatsoris, T; Nicolaides, C; Samantas, E; Skarlos, D; Syrigos, K; Xiros, N | 1 |
| Kadoyama, K; Niijima, S; Okuno, Y; Sakaeda, T; Seki, K; Shiraishi, Y; Yabuuchi, H | 1 |
| Bulter, M; Deghan Manshadi, S; Jerzak, KJ; Mackay, HJ; Maganti, M; McCuaig, JM; Ng, P; Oza, A | 1 |
4 trial(s) available for diphenhydramine and carboplatin
| Article | Year |
|---|---|
Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dexamethasone; Diphenhydramine; Drug Therapy, Combination; Endometrial Neoplasms; Female; Humans; Lorazepam; Metoclopramide; Ondansetron; Ovarian Neoplasms; Prochlorperazine; Severity of Illness Index; Single-Blind Method; Treatment Failure; Vomiting | 1994 |
Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Dexamethasone; Diphenhydramine; Drug Hypersensitivity; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2003 |
A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carboplatin; Carcinoma; Combined Modality Therapy; Dexamethasone; Diphenhydramine; Disease-Free Survival; Drug Administration Schedule; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hyperglycemia; Life Tables; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Premedication; Survival Analysis; Treatment Outcome; Urologic Neoplasms; Urothelium | 2004 |
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cimetidine; Deoxycytidine; Dexamethasone; Diphenhydramine; Female; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Ondansetron; Paclitaxel; Premedication; Proportional Hazards Models | 2008 |
6 other study(ies) available for diphenhydramine and carboplatin
| Article | Year |
|---|---|
Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions.
Topics: Anaphylaxis; Anti-Allergic Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carboplatin; Child, Preschool; Desensitization, Immunologic; Diphenhydramine; Drug Hypersensitivity; Histamine H2 Antagonists; Humans; Infant; Male; Prednisolone; Premedication; Ranitidine | 1996 |
Hepatic artery administration of paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cimetidine; Combined Modality Therapy; Dexamethasone; Diphenhydramine; Etoposide; Hepatic Artery; Humans; Injections, Intra-Arterial; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Premedication | 1999 |
Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
Topics: Adult; Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Diphenhydramine; Etoposide; Evaluation Studies as Topic; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Infusion Pumps; Infusions, Intravenous; Lorazepam; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Nausea; Patient Acceptance of Health Care; Prospective Studies; Safety; Self Care; Thiotepa; Vomiting | 1999 |
[Paclitaxel plus carboplatin in ovarian cancer-comparison of adverse effects between monthly and weekly administration].
Topics: Adult; Aged; Anorexia; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dexamethasone; Diarrhea; Diphenhydramine; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Nausea; Ovarian Neoplasms; Paclitaxel; Ranitidine; Retrospective Studies; Thrombocytopenia | 2004 |
Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Bayes Theorem; Carboplatin; Cisplatin; Data Mining; Databases, Factual; Dexamethasone; Diphenhydramine; Drug Hypersensitivity; Drug Therapy, Combination; Humans; Organoplatinum Compounds; Oxaliplatin; United States; United States Food and Drug Administration | 2011 |
Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Diphenhydramine; Drug Hypersensitivity; Female; Histamine H1 Antagonists; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prospective Studies; Retrospective Studies; Risk Factors | 2018 |